In vitro testing discloses EMD638683 as a SGK1 inhibitor with an IC50 of 3 μM. EMD638683 treatment significantly augments the radiation‑induced decrease of forward scatter, increase of phosphatidylserine exposure, decrease of mitochondrial potential, increase of caspase 3 activity, increase of DNA fragmentation and increase of late apoptosis.